CN101426511A - 化学修饰的祖细胞生成素连接物 - Google Patents

化学修饰的祖细胞生成素连接物 Download PDF

Info

Publication number
CN101426511A
CN101426511A CNA028165179A CN02816517A CN101426511A CN 101426511 A CN101426511 A CN 101426511A CN A028165179 A CNA028165179 A CN A028165179A CN 02816517 A CN02816517 A CN 02816517A CN 101426511 A CN101426511 A CN 101426511A
Authority
CN
China
Prior art keywords
mutagen
prt
unknown
progp
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028165179A
Other languages
English (en)
Chinese (zh)
Inventor
N·R·西格尔
R·F·芬恩
R·L·希尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PharMetrix Corp
Original Assignee
PharMetrix Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PharMetrix Corp filed Critical PharMetrix Corp
Publication of CN101426511A publication Critical patent/CN101426511A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CNA028165179A 2001-06-22 2002-06-14 化学修饰的祖细胞生成素连接物 Pending CN101426511A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30036201P 2001-06-22 2001-06-22
US60/300,362 2001-06-22

Publications (1)

Publication Number Publication Date
CN101426511A true CN101426511A (zh) 2009-05-06

Family

ID=23158770

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028165179A Pending CN101426511A (zh) 2001-06-22 2002-06-14 化学修饰的祖细胞生成素连接物

Country Status (15)

Country Link
US (1) US20060052291A1 (https=)
EP (1) EP1404354A4 (https=)
JP (1) JP2005512951A (https=)
KR (1) KR20040069980A (https=)
CN (1) CN101426511A (https=)
BR (1) BR0211192A (https=)
CA (1) CA2450950A1 (https=)
CZ (1) CZ20033537A3 (https=)
EA (1) EA006368B1 (https=)
IL (1) IL159496A0 (https=)
MX (1) MXPA04000068A (https=)
NO (1) NO20035742L (https=)
PL (1) PL367410A1 (https=)
WO (1) WO2003000179A2 (https=)
ZA (1) ZA200309863B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111565736A (zh) * 2017-10-11 2020-08-21 礼蓝美国股份有限公司 猪g-csf变体和其用途

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006215823A1 (en) * 2005-02-16 2006-08-24 Micromet Ag Use of activated polymers for separation of protein and polypeptide multimers
WO2006102659A2 (en) * 2005-03-23 2006-09-28 Nektar Therapeutics Al, Corporation CONJUGATES OF AN hGH MOIETY AND A POLYMER
US8951769B2 (en) 2009-04-20 2015-02-10 The Regents Of The University Of California Engineered demeter 5-methylcytosine DNA glyosylase with improved yield, stability and solubility
KR200483859Y1 (ko) 2015-10-28 2017-07-04 주식회사 키유틸리티 충전장치 수납 및 휴대용 기기 거치용 장치
CN111741770A (zh) * 2017-12-29 2020-10-02 豪夫迈·罗氏有限公司 用于提供聚乙二醇化蛋白质组合物的方法
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69431295T2 (de) * 1993-04-21 2003-05-15 Institut Pasteur, Paris Biokompatibles implantat zur in vivo expression und sekretion von therapeutischer verbindung
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
GB2294047A (en) * 1994-10-14 1996-04-17 Merck & Co Inc Synthetic peptides for use as epitopes specific for HIV
SE507527C2 (sv) * 1996-10-11 1998-06-15 Ericsson Telefon Ab L M Flerbandsmottagare som genererar en mellanfrekvens som är gemensam för de olika frekvensbanden, och förfarande för densamma
US6251665B1 (en) * 1997-02-07 2001-06-26 Cem Cezayirli Directed maturation of stem cells and production of programmable antigen presenting dentritic cells therefrom

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111565736A (zh) * 2017-10-11 2020-08-21 礼蓝美国股份有限公司 猪g-csf变体和其用途
CN111565736B (zh) * 2017-10-11 2024-03-08 礼蓝美国股份有限公司 猪g-csf变体和其用途

Also Published As

Publication number Publication date
EA006368B1 (ru) 2005-12-29
KR20040069980A (ko) 2004-08-06
WO2003000179A2 (en) 2003-01-03
BR0211192A (pt) 2004-10-26
CZ20033537A3 (cs) 2004-08-18
NO20035742D0 (no) 2003-12-19
WO2003000179A3 (en) 2003-12-11
PL367410A1 (en) 2005-02-21
NO20035742L (no) 2004-02-23
ZA200309863B (https=) 2006-06-28
US20060052291A1 (en) 2006-03-09
JP2005512951A (ja) 2005-05-12
EP1404354A2 (en) 2004-04-07
IL159496A0 (en) 2004-06-01
EA200400070A1 (ru) 2004-06-24
CA2450950A1 (en) 2003-01-03
MXPA04000068A (es) 2005-06-06
EP1404354A4 (en) 2005-04-20

Similar Documents

Publication Publication Date Title
AU2022268401B2 (en) Conjugates of an IL-2 moiety and a polymer
KR100303810B1 (ko) 거핵구성장및분화를자극하기위한조성물및방법
AU634343B2 (en) Modified hil-6
CA2978330C (en) Conjugates of an il-7 moiety and a polymer
CA2617064A1 (en) Conjugates of a g-csf moiety and a polymer
US20140044672A1 (en) Conjugates of a gm-csf moiety and a polymer
CN101426511A (zh) 化学修饰的祖细胞生成素连接物
KR20070010817A (ko) 인간 과립구콜로니자극인자 변이체 및 이의 화학적 접합물
WO2001076639A2 (en) Chemically-modified myelopoietin conjugates
US20090203589A1 (en) Chemically modified human growth hormone receptor antagonist conjugates
AU2002315117A1 (en) Chemically-modified progenipoietin conjugates
CN116212040A (zh) 一种作为Treg靶向调节剂的PEG修饰IL-2的组合物及其制备方法和用途
HK40053166A (en) Conjugates of an il-2 moiety and a polymer
KR20070064418A (ko) 인간 과립구콜로니자극인자 변이체 및 이의 화학적 접합물
CN101172160A (zh) 干扰素γ偶联物
PL183631B1 (pl) Pochodna polipeptydu stanowiącego czynnik wzrostu i rozwoju megakariocytów-(polipeptydu MGDF), sposób jej wytwarzania oraz kompozycja farmaceutyczna zawierająca taką pochodną

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090506